After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
Zacks.com on MSN1h
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock RisesAxsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...
New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...
A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study led by Western researchers suggests that frequent treatment with intranasal o ...
The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...
A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...
Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.
The interim leader of the National Institutes of Health gave some clarification tied to Trump administrations restrictions on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback